Two big shockers on Monday: We saw little fuss over GLD's decline and the vexing VIX move.
While there's every reason to be cautious, the technicals show a good opportunity to make money before the new year.
The stock market has gone essentially nowhere since the news from Pfizer about a vaccine; expect more overbought and high complacency.
Let's look at an indicator I rarely discuss: The percentage of S&P 500 stocks that are trading over their 200-day moving average.
Yes, this exercise in pulling back is boring, but it's how we work off the overbought reading and complacency.
Let's break down how the past week played out, and see what's likely ahead.
We just got a good start to an overbought pullback. Now let's check in on sentiment.
The either/or market continues -- but let's take a closer look at what's really just a giant trading range.
The mega-cap types just can't seem to get together with everyone else -- and, here's why we still look different now from the 2016 election period.
The market is looking ahead to the final couple of months to the year and what might be in store for 2021.